These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 35908569)

  • 1. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
    RECOVERY Collaborative Group
    Lancet; 2022 Jul; 400(10349):359-368. PubMed ID: 35908569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
    Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
    Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
    ;
    Lancet; 2023 May; 401(10387):1499-1507. PubMed ID: 37060915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet Respir Med; 2021 Dec; 9(12):1419-1426. PubMed ID: 34672950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2021 Feb; 397(10274):605-612. PubMed ID: 33545096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
    Wolfe CR; Tomashek KM; Patterson TF; Gomez CA; Marconi VC; Jain MK; Yang OO; Paules CI; Palacios GMR; Grossberg R; Harkins MS; Mularski RA; Erdmann N; Sandkovsky U; Almasri E; Pineda JR; Dretler AW; de Castilla DL; Branche AR; Park PK; Mehta AK; Short WR; McLellan SLF; Kline S; Iovine NM; El Sahly HM; Doernberg SB; Oh MD; Huprikar N; Hohmann E; Kelley CF; Holodniy M; Kim ES; Sweeney DA; Finberg RW; Grimes KA; Maves RC; Ko ER; Engemann JJ; Taylor BS; Ponce PO; Larson L; Melendez DP; Seibert AM; Rouphael NG; Strebe J; Clark JL; Julian KG; de Leon AP; Cardoso A; de Bono S; Atmar RL; Ganesan A; Ferreira JL; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd LE; Beigel JH; Kalil AC;
    Lancet Respir Med; 2022 Sep; 10(9):888-899. PubMed ID: 35617986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2022 Jan; 399(10320):143-151. PubMed ID: 34800427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet Diabetes Endocrinol; 2023 Dec; 11(12):905-914. PubMed ID: 37865101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2021 May; 397(10285):1637-1645. PubMed ID: 33933206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2021 May; 397(10289):2049-2059. PubMed ID: 34000257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2020 Oct; 396(10259):1345-1352. PubMed ID: 33031764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    Chen CY; Chen WC; Hsu CK; Chao CM; Lai CC
    Int Immunopharmacol; 2021 Oct; 99():108027. PubMed ID: 34343937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.
    Hall FC; Cheriyan J; Cope AP; Galloway J; Wilkinson I; Bond S; Norton S; Banham-Hall E; Bayes H; Kostapanos M; Nodale M; Petchey WG; Sheeran T; Underwood J; Jayne DR;
    Lancet Respir Med; 2023 Dec; 11(12):1064-1074. PubMed ID: 37977159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet Child Adolesc Health; 2024 Mar; 8(3):190-200. PubMed ID: 38272046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
    Butler CC; Yu LM; Dorward J; Gbinigie O; Hayward G; Saville BR; Van Hecke O; Berry N; Detry MA; Saunders C; Fitzgerald M; Harris V; Djukanovic R; Gadola S; Kirkpatrick J; de Lusignan S; Ogburn E; Evans PH; Thomas NPB; Patel MG; Hobbs FDR;
    Lancet Respir Med; 2021 Sep; 9(9):1010-1020. PubMed ID: 34329624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
    PRINCIPLE Trial Collaborative Group
    Lancet; 2021 Mar; 397(10279):1063-1074. PubMed ID: 33676597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.